Tesamorelin: The FDA-Approved Peptide for Visceral Fat — Benefits, Dosage, and How to Get It
Medically reviewed by the Rite Aid Health Team · Last updated July 2, 2026
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), used to reduce excess visceral abdominal fat. It is FDA-approved — sold under the brand Egrifta — for reducing visceral fat in people with HIV-associated lipodystrophy, and it works by prompting the pituitary to release more of the body's own growth hormone.
That approval rests on human clinical trials showing measurable visceral-fat reduction, which sets tesamorelin apart from peptides supported mainly by animal data or user reports.
It is also used off-label for visceral fat and body composition, and it raises IGF-1 the way other GHRH analogs do. Compare it with other peptide therapy options if your goal is growth-hormone support rather than appetite control.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
What is tesamorelin?
Tesamorelin is a stabilized analog of the first 44 amino acids of growth-hormone-releasing hormone. Like other GHRH analogs, it signals the pituitary to release the body's own growth hormone in a natural pulsatile pattern, which then raises IGF-1.
What distinguishes it is that it went through the full FDA drug-approval process rather than remaining an off-label compounded peptide — it is an approved prescription medication for a specific indication.
FDA approval — why the evidence base matters
Tesamorelin is approved by the FDA under the brand name Egrifta for reducing excess visceral abdominal fat in patients with HIV-associated lipodystrophy.
The approval is backed by randomized controlled human trials demonstrating that tesamorelin reduces visceral adipose tissue — a far stronger evidence base than most peptides, which rest mainly on animal studies.
Compared with BPC-157 or CJC-1295, where human data is limited, tesamorelin has the opposite profile: its core indication is supported by registrational human trials. That clinical validation is the reason it is used as a reference point for GHRH-analog therapy generally.
Benefits and uses
Visceral fat reduction. The approved and best-evidenced use. In clinical trials, tesamorelin reduced visceral adipose tissue — the deep abdominal fat associated with metabolic risk — in the studied population. Body composition. Off-label, tesamorelin is used to improve body composition by raising GH and IGF-1, which favor lean mass and fat metabolism. Metabolic and other GH effects. As a GHRH analog it produces the broader effects of elevated growth hormone, including those on recovery and tissue repair.
The visceral-fat outcome is the one anchored in human trials. Off-label body-composition use extends from the same mechanism but outside the studied indication.
How it works
Tesamorelin binds the GHRH receptor on the pituitary and stimulates the synthesis and release of growth hormone. The released GH drives production of IGF-1 in the liver and other tissues, and acts on adipose tissue to promote the breakdown of fat — the mechanism behind the visceral-fat reduction seen in trials.
Because the signal runs through the body's own pituitary, GH is released in pulses rather than as a flat synthetic level.
Dosage and administration
Tesamorelin is given by subcutaneous injection, once daily. The approved Egrifta dosing is a fixed daily dose reconstituted and injected; off-label protocols follow the same daily subcutaneous route.
Because an FDA-approved product exists, the labeled dosing and administration instructions are the reference — and dosing should be set and supervised by a prescribing provider.
Reconstitution and drawing the right volume on an insulin syringe trips up most first-time users. Use the peptide dosage calculator to convert your target dose into syringe units for your vial size.
Side effects and safety
Because tesamorelin is FDA-approved, its side-effect profile is documented from clinical trials rather than estimated. Reported effects include injection-site reactions, joint pain (arthralgia), swelling and fluid retention, and muscle pain.
As a GH-raising agent it can affect blood sugar, so glucose should be monitored. It is not recommended in pregnancy or in people with active malignancy. Monitor IGF-1 and metabolic markers and work with a provider.
Legal status and how to get tesamorelin
Tesamorelin already has an established prescription pathway — it is an FDA-approved medication (Egrifta) available by prescription for its labeled indication. It was not part of the April 2026 reclassification, because it was never restricted as an unapproved compounded peptide; it is a fully approved drug.
For its approved use, it is obtained through a prescription filled at a pharmacy. Products sold online "for research use only" are not the approved product and are not quality-controlled for human use.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
Blood work to track tesamorelin
Tesamorelin raises GH and IGF-1 and affects metabolism, so tracking focuses on the IGF-1 readout and on metabolic safety:
IGF-1 — the direct marker for any GH-releasing peptide. It should rise if tesamorelin is working, and it's the number used to keep GH in a sensible range. Comprehensive metabolic profile — glucose, liver enzymes, and kidney function; the safety baseline, and the glucose monitoring that matters specifically for a GH-raising agent.
Test before you start and again during the cycle.
Baseline tests before a peptide cycle
Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.
Related peptides
Tesamorelin is one of several growth-hormone-releasing peptides. It is most often compared with Sermorelin and CJC-1295, the other GHRH analogs that raise the body's own growth hormone, and with MOTS-c, the mitochondrial-derived peptide studied for fat metabolism and insulin sensitivity.
For a broader plan, compare tesamorelin with peptides for weight loss and peptides for muscle and performance.
References
EGRIFTA (tesamorelin) FDA prescribing information DailyMed: EGRIFTA tesamorelin labeling PubMed: Tesamorelin and visceral adipose tissue studies
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.